



Registration No. 196801000315 (7916-A)

PRESS RELEASE

For Immediate Release

**GENTING BERHAD'S SUBSIDIARY, PT ASTANA BANGUN SEJAHTERA
BREAKS GROUND ON FONTAINE VITALE, ITS STEM CELL FACILITY TO
BE DEVELOPED IN THE SPECIAL ECONOMIC ZONE IN SANUR, BALI**

BALI, 20 November 2024 - Genting Berhad ("**GENT**") celebrated a significant milestone today with the groundbreaking ceremony of its first stem cell facility, "Fontaine Vitale", ("**Facility**") to be developed and operated by its indirect subsidiary, PT Astana Bangun Sejahtera ("**PT Astana**"), in the Special Economic Zone in Sanur, Bali ("**Sanur SEZ**"). PT Astana, which is 56% indirectly held by GENT, was set up in collaboration with two other Indonesian parties, namely, PT Sentosa Bersama Mitra and PT Bintang Graha Hijau.

The agreement to lease a 9,121 m² plot of land identified as Lot H3B in the Sanur SEZ ("**Lot H3B**") for 30 years, was signed by PT Astana and PT Hotel Indonesia Natour (the landowner) on 16 October 2024. The state-of-art Facility will be constructed and developed on Lot H3B and will serve both local and international patients seeking cutting-edge healthcare solutions.

Initiated by the Indonesian government as the country's first medical tourism special economic zone, the Sanur SEZ project aims to develop a comprehensive health and wellness ecosystem with state-of-the-art medical facilities, specialized clinics, wellness centers, research institutions, and supporting infrastructure to attract local and international patients seeking high-quality healthcare services in a serene and rejuvenating environment.

Fontaine Vitale will leverage on GENT's strategic partnership with Celularity Inc ("**Celularity**") (Nasdaq: CELU), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, to bring Celularity's experience and proprietary technology in cellular and regenerative medicine, and Celularity's products to the Facility.

The 4 storey Facility will be developed in two phases:

- Firstly, a stem cell clinic ("**Clinic**") will be established at the Facility, offering advanced cell therapy services focused on wellness, aesthetics, and regenerative medicine using placenta-derived stem cells produced by Celularity in its US facility.
- In the second phase, it is contemplated that a manufacturing facility will be set up at the Facility, where all cells required for use in the Clinic or for supply to other hospitals and clinics will be manufactured on-site under the license and supervision of Celularity.



Registration No. 196801000315 (7916-A)

PRESS RELEASE

For Immediate Release

Fontaine Vitale will also showcase diagnostic products developed by companies in GENT's life sciences portfolio, including enhanced imaging with AI solutions to help improve disease prediction and diagnosis as well as tools for early diagnosis and monitoring of disease progression in dementia.

Tan Sri Lim Kok Thay, Chairman and Chief Executive of GENT said: *"Genting Berhad is very excited to be part of the Sanur SEZ vision to be a world class medical and wellness destination. Our state-of-the-art cutting edge wellness and health centre, located next to the Bali International Hospital, signals Genting Group's entry into the healthcare sector and our commitment to bring to ASEAN the opportunities presented by our life sciences investments."*

Dato' Sri Tan Kong Han, the President, Chief Operating Officer and Executive Director of GENT added: *"The stem cell clinic, which is the core within our Fontaine Vitale facility, is expected to commence commercial operations towards the end of 2026. This clinic will be the first in ASEAN to offer placenta-derived allogeneic stem cell therapy, focusing on well-being, aesthetics and regenerative medicine. The stem cells will be manufactured in an FDA-approved cGMP facility, ensuring the highest standards of quality and safety. This project reflects Genting Group's commitment to pioneering innovative healthcare solutions and addressing the growing demand for advanced medical treatments in the region. We believe this facility will not only enhance the healthcare landscape in ASEAN but also position Bali as a key hub for medical tourism, attracting patients from around the world seeking cutting-edge regenerative therapies."*

Sumantri Suwarno, the President Commissioner of PT Astana commented: *"PT Astana, with the support of Genting Group and Celularity, aims to seize the tremendous opportunity provided by the Sanur SEZ to bring world-class stem cell technology services. This initiative will complement Bali's reputation not only as a tourism destination but also as a provider of global-standard healthcare services for the Indonesian market and the broader Asian region."*

"We are thrilled to collaborate with Genting Group and PT Astana to bring placenta-derived allogeneic stem cell therapy to ASEAN," Dr. Robert Hariri, founder, Chairman and CEO of Celularity said. *"This partnership highlights our commitment to expanding access to advanced cellular therapies focused on wellness, aesthetics, and regenerative medicine. The new clinic in Sanur, Bali, will leverage Celularity's proprietary technology to provide high-quality stem cells and advanced biomaterial products, marking a significant step in our mission to deliver innovative medical treatments globally. We look forward to the positive impact this facility will have on the region's healthcare landscape."*



The Groundbreaking Ceremony for Fontaine Vitale on 20 November 2024

Signing of Minutes of Land Handover by Mr Bonny Harry, President Director, PT Astana Bangun Sejahtera (second from left) and Ms Christine Hutabarat, President Director PT Hotel Indonesia Natour (second from right), witnessed by Dato' Sri Tan Kong Han, President, Chief Operating Officer and Executive Director of Genting Berhad (first from left) and Mr Herdy Harman, Director SDM and Digital PT Aviassi Pariwisata Indonesia (Persero) (first from right).



The Groundbreaking Ceremony for Fontaine Vitale on 20 November 2024

from left to right:

Mr Gregorius Yolodi Supie and Ms Marie Rosantina (Yolodi + Marie Architects), Mr Edrick Budhiparama (Director, PT Astana Bangun Sejahtera), Dato' Sri Tan Kong Han (President, Chief Operating Officer and Executive Director of Genting Berhad), Mr Bonny Harry (President Director, PT Astana Bangun Sejahtera), Ms Christine Hutabarat (President Director PT Hotel Indonesia Natour), Mr Herdy Harman (Director SDM and Digital, PT Aviassi Pariwisata Indonesia (Persero)), Dr Yanti Herman, SH. Mhkes. (Director, Quality of Health Service, Ministry of Health of the Republic of Indonesia), Dr Ida Bagus Anom Suryadiputra, M.H (Chief Administrator, Sanur and Kura Kura Bali Special Economic Zone, Indonesia) and Mr Doddy Matondang (President Director, PT Hotel Internasional Sanur Indonesia).



Registration No. 196801000315 (7916-A)

PRESS RELEASE

For Immediate Release

About GENTING:

Genting Berhad is principally an investment holding and management company. While the Company was incorporated in 1968 and listed in 1971, the Genting Group was founded in 1965 when its Founder, the late Tan Sri Lim Goh Tong started the journey to realise his vision of building a mountaintop resort in Malaysia. Today, the Genting Group comprises Genting Berhad and its listed companies; Genting Malaysia Berhad, Genting Plantations Berhad and Genting Singapore Limited, as well as its wholly owned unlisted subsidiaries Genting Energy Limited and Resorts World Las Vegas LLC.

Led by Tan Sri Lim Kok Thay, the Group is involved in leisure and hospitality, oil palm plantations, power generation, oil and gas, property development, life sciences and biotechnology activities, with operations spanning across the globe, including in Malaysia (the Group's country of origin), Singapore, Indonesia, India, China, the United States of America, Bahamas, the United Kingdom and Egypt. In the core leisure and hospitality business, the Genting Group markets and offers a suite of products under a number of premier brands including **Genting, Resorts World, Genting Grand, Genting Club, Crockfords and Maxims**. The Genting Group has tie ups with established names such as Universal Studios, Premium Outlets, Zouk, Hard Rock Hotel, Hilton, Hyatt and other renowned international brand partners.

For more information, visit www.genting.com.

For media editorial, please contact:

Genting Berhad
Curation & Communications dept
T: 603 2178 2288 / 2333 2288
E: curation@genting.com

About Celularity

Celularity Inc. (NASDAQ: CELU) is an innovative regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. What sets Celularity apart is its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity's unique approach, harnessing the placenta's biology and ready availability, is paving the way for therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

For more information, visit <https://celularity.com/>

- END OF RELEASE -